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Quantitative alterations of antigen-presenting cells (APC) in 
(pre)neoplastic lesions of the uterine cervix associated with human 
papillomavirus (HPV) infection suggest a diminished capacity to 
capture viral antigens and to induce a protective immune response.  
Method of study 
To test if a cervical application of GM-CSF could restore an immune 
response against HPV in women with cervical low-grade squamous 
intraepithelial lesions (LSIL). We performed two clinical trials with11 
healthy women and 15 patients with LSIL.  
Results 
GM-CSF applications were well tolerated in all enrolled women and no 
difference in toxicity between the treated and placebo groups was 
observed during the follow up (until 30 months). Interestingly, in the 
GM-CSF treated group, a significant increased APC and cytotoxic T 
lymphocyte infiltration was observed in the cervical biopsies with no 
change in regulatory T cell numbers. All the HPV16+ patients exhibited 
an immune response against HPV16 after GM-CSF applications, as 
shown by NK and/or T cells producing IFN-γ whereas no cellular 
immune response was observed before the treatment. Moreover, the 
anti-VLP antibody titers also increased after the treatment.  
Conclusion 
These encouraging results obtained from a limited number of subjects 
justify further study on the therapeutic effect of APC in cervical 
(pre)neoplastic lesions.   
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Even if prophylactic vaccines against human papillomavirus (HPV) are 
now available, morbidity and mortality caused by HPV infection still 
represent a major health problem with very high direct and indirect 
costs 1. Furthermore, the protection is restricted to 2 HPV types 
involved in 30-70% of pre-cancerous lesions (squamous intraepithelial 
lesions, SIL). Incomplete type coverage is especially problematic in 
developing countries where no effective screening programs are 
available as an alternative approach for reducing cervical cancer risk 
associated with minor oncogenic HPV types. The vaccination blocks 
HPV primary infection by inducing high titers of neutralizing antibodies, 
but does not accelerate clearance of the virus in pre-existing infections 
2. This could be linked to the fact that cell-mediated immunity is critical 
for the clearance of HPV-associated lesions 3-5. Moreover, the current 
surgical methods for treating SIL may generate complications, e.g. 
pregnancy complications 6 and persistence and/or recurrence of SIL 
occur in 5–25% of patients 7. All these facts underlie the need for other 
therapeutic protocols. 
Most SIL are characterized by a decreased density and function of 
antigen-presenting cells such as dendritic and Langerhans cells 
(DC/LC) in comparison with the normal paired squamous epithelium8, 9. 
However, Granulocyte Macrophage–Colony Stimulating factor (GM-
CSF) can restore the colonization of DC/LC in a neoplastic epithelium 
transplanted in vivo in NOD/SCID mice 10. This cytokine is produced by 
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keratinocytes and a correlation has been observed in vivo between the 
levels of GM-CSF produced by some carcinomas and the 
distribution/differentiation of tumor-associated DC 11. Moreover, in vitro 
DC specifically induce apoptosis of keratinocytes transformed by HPV, 
whereas normal keratinocytes are not affected 12. This apoptotic effect 
of DC is not restricted to HPV-transformed keratinocytes. Manna et al. 
13 have also demonstrated a direct tumoricidal effect of DC on breast 
carcinoma cells. The safety of GM-CSF injected subcutaneously 14, 15 
or intradermally 16 to patients with cancer was previously evaluated, but 
to our knowledge, the tolerability of topical GM-CSF applications on a 
mucosal surface has never been assessed.  
The purpose of this study was to establish a proof of concept for a 
treatment based on local applications of a GM-CSF-containing gel. We 
therefore evaluated the safety and the ability of this gel to induce the 
recruitment of DC/LC and lymphocytes into an epithelium infected by 
HPV and to elicit an immune response against HPV-infected cells. In 
order to have a long follow up (more than 6 months this study was 
performed on patients with low-grade SIL (LSIL) to circumvent the risk 
of cancer development.  
Materials and Methods 
Patients 
Eleven women without cervical lesions were enrolled for a phase Ia 
clinical trial. For safety reasons and to be able to have a 6-month follow 
up without treatment, we chose to include in phase Ib clinical trial 
patients with LSIL. The eligibility criteria for patients were the 
persistence of LSIL and/or detection of oncogenic HPV for a minimum 
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of three months with a median of 8.5 months for the GM-CSF group 
and 6 months for the placebo group (no statistical difference). One 
hundred ninety two patients were screened and fifteen patients with 
LSIL were enrolled (Fig. 1, Table 1).  
Vital signs (heart rate, blood pressure and oral temperature), local 
symptoms (pain, redness, swelling, inflammation), serious and other 
adverse events were recorded in the Case Report Form (CRF) of each 
patient. 
HPV genotyping was determined using a PapilloCheck Test Kit (gift 
from Greiner Bio One, Frickenhausen, Germany)17 (Table 1) and the 
viral load of oncogenic HPV was estimated by Hybrid Capture II 
(Digene, Venlo, Netherlands) at the first (visit A) or the second visit (B) 
and at the end of the clinical protocol.  
These clinical protocols were approved by the local ethics committee of 
the University Hospital of Liège.  
Clinical protocol  
Patients received 1 (healthy women) or 4 (patients with LSIL) 
applications of 3-4 ml GM-CSF (or placebo) in polycarbophil gel 
separated by 3 days. They were followed for one week or for a period 
of 6-7 months for the phase Ia and the phase Ib clinical trial, 
respectively. A late visit (26-30 months) was also performed for the 
phase Ib clinical trial.  
The polycarbophil gel (1.0% w/w) was prepared by dispersing Noveon 
AA1 (Noveon, Brussels, Belgium) in purified water. The mixture was 
stirred until thickening occurred and was then neutralized by drop wise 
addition of 40% (w/w) tromethamol, until a transparent gel appeared. 
The quantity of tromethamol was adjusted to achieve a gel of pH 5.5 10. 
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For the active formulation, GM-CSF (Amoytop Biotech, Xiamen, China) 
was incorporated into the hydrogel at a concentration of 400,000 IU/ml, 
800,000 IU/ml or 1,000,000 IU/ml for the phase Ia clinical trial and 
800,000 IU/ml for the phase Ib clinical trial. The first administration of 
the gel was made by a senior gynecologist. The other applications 
were self-administered at bedtime with a polystyrene applicator (Besins 
Healthcare, Belgium). 
At visit A (week -35 to -5) and B (week -21 to -1) a colposcopy and 
sampling for viral detection and DNA load determination were 
performed. GM-CSF or the placebo gel was applied at visit C (Week 0). 
Follow up was performed at visit D (week 2), visit E (week 6 to 15) and 
visit F (week 23 to 42).  
Keratinocyte proliferation assay 
Normal keratinocytes (KN), HaCat cell line and HPV-transformed 
keratinocyte cell lines (CK2, CaSki, SiHa and KT1F4) were cultured 
(5X103 cells/well) in 96-well plates (Nunclon Surface, NUNC) with or 
without GM-CSF (63µg/ml-800 000 U/ml). Proliferation was measured 
after 48h at 37°C, following an 18 h incubation with 0.4µCi/well of 
[³H]thymidine (6.7Ci/mmol, Moravek Biochemicals, Brea, CA). DNA 
was harvested by an automated sample harvester (Packar, Canberra, 
Tilburg, The Netherlands) and thymidine incorporation was analyzed 
using a liquid scintillation counter (Top Count, Packard, Canberra).  
The assessment of cell proliferation in vivo was performed on biopsies 
by using an anti-Ki-67 antigen antibody (clone MIB-1 from Dako) 
following a previously described procedure 8. Ki-67 antigen staining 
was evaluated by analyzing the localization of positive cells and 
8 
expressing the proliferation as normal when the positive cells were 
present in the basal layer, low when positive cells reached the first third 
of the epithelium and moderate to high when the positive cells were 
present in the second or the last third of the epithelium. 
Immunostaining and systemic immune response 
The density of immune cells in biopsies was assessed by 
immunoperoxidase detection with anti-CD1a (Novocastra, Newcastle, 
UK) and anti-CD8 (Dako, Glostrup, Denmark) monoclonal antibodies 
(mAb) for DC/LC and CTL, respectively, as described previously 18.  NK 
cells were detected with NKp46 mAb (R&D Systems, Oxon, Belgium) 
and regulatory T cells (Treg) were stained with Foxp3 mAb 
(eBiosience, UK). The results were expressed as ratios by dividing the 
values obtained after treatment by the values before treatment.  
The cellular immune response was evaluated by IFN-γ  intracellular 
staining on PBMC stimulated with the E7 HPV16 protein (gift from GSK 
Biologicals, Rixensart, Belgium) and L1 HPV16 Virus-like particles 
(VLP) at each visit as described previously 19. Briefly, PBMC (2 x 
106/ml) in 5 ml round bottom polypropylene tubes containing X-vivo 20 
medium (BioWhittaker, Cambrex Bio Science, Verviers, Belgium, 
supplemented with 20 U/ml IL-2) were cultured overnight at 37 °C with 
or without the E7 HPV16 protein and L1 HPV16 VLP. HPV16 VLP were 
produced in insect cells using a recombinant baculovirus encoding 
HPV 16 L1 protein and were purified as previously described20. 
Brefeldin A (10 µg/ml, Sigma, St. Louis, MO) was added during the last 
4 h of culture. After stimulation, cells were stained for cell surface 
molecules at 4 °C for 20 min with anti-CD4-PE, anti-CD8-PerCP, anti-
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CD3-PerCP, anti-CD16-PE and anti-CD56-PE (Becton Dickinson 
Erembodegem, Belgium). After washing with PBS, cells were fixed and 
permeabilized with FacsLyse and FacsPerm respectively (Becton 
Dickinson) according to the manufacturer’s instructions. After an 
additional washing with PBS, the cells were stained with anti-IFN-γ-
FITC (Becton Dickinson) for 20 min at room temperature. After another 
washing, cells were resuspended in 400 µl of 1% paraformaldehyde in 
PBS and acquisition was performed within 24 h on more than 100,000 
events per staining with a flow cytometer (Facsvantage, Becton-
Dickinson). Analysis was performed using CellQuest on an SSC/FSC 
gate on viable lymphocytes. Results were expressed as the 
percentages of cytokine positive cells in the defined cell population 
after background (no activator) was subtracted. Overnight supernatants 
from PBMC cultures were stored at –70°C and analyzed for IFN-γ 
content in a specific capture ELISA according to the manufacturer’s 
instructions (R&D Systems).  
Plasma samples were used for serological testing for HPV16 and 31 by 
ELISA assays with HPV16 and 31 VLP L1 as described previously21.  
 
Statistical analysis  
Statistical analysis was performed using the Student’s t test. The 
calculation of power gave values from 92% to 39% according to the SD 
(from 0.4 to 0.8; 49% for weighted SD= 0.7). All calculations were 





Even if GM-CSF was already used in clinical trials 14-16, we performed 
pre-clinical studies because GM-CSF was described to mildly stimulate 
the growth of HaCat keratinocyte cell line 22. We confirmed previous 
results showing the stimulation of HaCat cell proliferation and a slight 
increased growth of normal keratinocytes, but no significant effect was 
detected with 4 different HPV+ cell lines (Fig. 2a). 
The phase Ia clinical trial was performed because there was no 
previous information about the potential toxicity of mucosal applications 
of GM-CSF. The doses used were extrapolated from our data obtained 
in a murine model 10. This clinical trial was conducted on 11 normal 
women with normal cervical cytology (Table 1) who received one 
application gel containing 400,000 IU/ml (4 women), 800,000 IU/ml (4 
women), 1,000,000 IU/ml (3 women) of GM-CSF. Since no adverse 
effect was reported, we decided to compare 4 applications of the gel 
containing the intermediate dose (800,000 IU/ml, n=10) with a placebo 
gel (n=5) in a second clinical trial including patients with LSIL (Table 1). 
All women encountered none or only minor and transient side effects 
with no difference between women receiving gel with or without GM-
CSF. All patients were examined by gynecologists 6 to 30 months after 
the second clinical trial and no side effects related to the trial were 
reported.  
To further assess the absence of keratinocyte proliferation in the 
presence of topical application of GM-CSF, we also performed an anti-
Ki67 labeling 23 on biopsies taken before or after treatment (visit D and 
F:  2 weeks and 5 to 10 months after the GM-CSF application, 
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respectively). No statistical significant modification in the proliferative 
index of epithelial cells was observed in women treated with GM-CSF 
in comparison with the placebo group (Fig. 2b). 
 
Immune response 
DC/LC, cytotoxic T lymphocytes (CTL) density in biopsies was 
monitored by CD1a (Fig. 3a) and CD8 (Fig. 3b-c) immunostaining, 
respectively. The different types of staining were scored as previously 
described 18 and the results were expressed as ratios compared to the 
scores obtained before treatment. Significantly higher ratio of CD1a 
positive cells was observed at visit F (p=0.0197) in GM-CSF-treated 
group versus placebo (Fig. 3a). GM-CSF also induced similar results 
for CD8+ T cells, significant data were obtained for visit F in the stroma 
adjacent to the lesion (p=0.040; Fig. 3b-c). However, the scores of 
CD1a and CD8 staining were generally higher in the placebo group 
before the start of the clinical trial (data not shown). NK cells were 
detected with an NKp46 antibody in cervical biopsies (Fig. 3d). Since 
the number of NKp46+ cells was low in cervical biopsies, we counted 
the cells instead of scoring. In the epithelium only few cells were 
detected (data not shown). In the stroma, an increased NK infiltration 
was observed at visit D (p=0.029) (Fig. 3d).  
We also counted the number of Foxp3+ Treg (Fig. 4 a-b). We were not 
able to obtain ratios for the infiltration in the epithelium because Treg 
were not detected in several cervical biopsies (Fig. 4a). Both in the 
epithelium and in the stroma, we did not observe a significant increase 
of Foxp3+ Treg after treatment except for one patient in GM-CSF group 
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(Fig. 4 a-b). Interestingly, the patient G2 with the highest number of 
Foxp3+ Treg cells (empty symbol in Fig. 4) showed a low score of 
CD8+ T cells in the epithelium (empty symbol in Fig. 3b), but not in the 
stroma or for NK cells (empty symbol in Fig 3c-d). The number of Treg 
decreased at visit F (empty symbol in Fig. 4), whereas both CD8+ T 
and NK cells increased (empty symbol in Fig. 3b-d).  
Systemic immune responses were also evaluated against HPV16 and 
31. Three patients were HPV16+ (all in GM-CSF group), which is in 
concordance with the prevalence of HPV16 in LSIL (24%) in Belgium 24 
and two patients were HPV31+ (one in GM-CSF and one in placebo 
group). No T cell response was observed before treatment. There was 
a substantial increase in the percentage of IFNγ+ cells in PBMC from 
the 3 patients (G4, G5 and G10), who had received GM-CSF (Fig. 5a-
b). Depending on the patient and the type of stimulation (E7 or L1-
VLP), IFNγ producing cells were T lymphocytes (CD8+ or CD4+) or NK 
cells. In patients G4 and G5, the number of IFNγ+ cells dropped at 
week 23-42 after the treatment (Fig. 5a-b). We also observed an 
increased secretion of IFNγ in response to E7 and L1-VLP by ELISA 
assay, except for patient G10 (data not shown). We tested the anti-
HPV16 response in PBMC from the 12 patients negative for HPV16. A 
trend for a higher percentage of lymphocytes expressing IFNγ after 
stimulation with HPV16 L1-VLP was observed in the GM-CSF group in 
comparison with the placebo patients (data not shown).  
Before treatment no antibodies or low titers (except for the patient 
HPV16+ G10) against HPV16 and HPV31 VLP were observed (data 
not shown).  For all the HPV16+ patients (G4, G5 and G10), antibodies 
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against HPV16 VLP were detected after treatment with GM-CSF (Fig. 
5c). Interestingly, the antibody titer in the serum of patient G4 was very 
high and similar to those observed after vaccination with HPV16 VLP. 
Both HPV31+ patients (G4-P1) had antibodies against HPV31 VLP but 
the patient receiving GM-CSF (G4) had a higher concentration of 
antibodies than the patient (P1) in the placebo group (Fig. 5d).  
Clinical response  
The clinical status (grade of SIL and viral load) was also checked in the 
15 patients enrolled in the phase Ib study. Despite the detection of an 
immune response, we were not able to observe any difference in 
clinical response, the proportion of patients showing regression or 
progression was similar in both groups (data not shown). This could be 
linked to the small cohort of patients, to the high spontaneous 
regression rate of LSIL 25 or to the fact that GM-CSF-treated patients 
presented, in our study, negative factors (multiple infections, higher 
viral load and significantly older age (p=0.03) 26) than those of the 
placebo-group (Table 1).  
 
Discussion 
In this study, we first demonstrated that the intraepithelial recruitment of 
antigen-presenting cells by topical applications of GM-CSF is safe and 
well tolerated (Fig. 2 and Table 1). This is in contrast with other 
immunomodulators used topically to treat HPV-associated lesions such 
as imiquimod 27-31. Moreover, GM-CSF did not induce proliferation of 
keratinocytes transformed by HPV both in vitro and in vivo (Fig. 2).  
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Interestingly, the recruitment of DC/LC in SIL was associated with an 
immune response against HPV in HPV16+ patients. Our previous work, 
both in vitro and in a murine model of HPV-induced intraepithelial 
neoplasia, demonstrated that GM-CSF is able to stimulate the 
migration of DC/LC in an epithelium transformed by HPV 32. We also 
observed this migration in GM-CSF-treated patient biopsies (Fig. 3 a). 
A higher infiltration of CD1a+ cells was previously described in vulvar 
intraepithelial lesions in patients who responded to a therapeutic 
vaccine against HPV, illustrating the importance of APC in the induction 
of immune response against HPV 33. Other immunotherapy protocols 
using tumor cells engineered to secrete GM-CSF also showed 
increased numbers of activated APC at the immunotherapy injection 
sites and in draining lymph nodes 34.  
In similar clinical protocols, dense lymphocyte infiltrates were observed 
at injection sites in the majority of patients 35. In our study, we observed 
an increased infiltration of cytotoxic cells such as NK cells and CD8+ 
lymphocytes (Fig. 3b-d). Interestingly, the expression of NK receptor 
ligands was described on cervical tumor cells 36, suggesting that NK 
cells can recognize and kill these cells. In a mouse model, tumor 
protection induced by GM-CSF was shown to be CD8 T cell dependent 
37 and the persistence of HPV16 infection was associated with the lack 
of cytotoxic T lymphocyte response in human 38. As already described 
in other immunotherapy protocols 39, we observed Foxp3+ Treg cells in 
cervical biopsies (Fig. 4). These cells could inhibit the anti-tumoral 
response 40, but GM-CSF treatment did not induce a significant 
increase of these cells (Fig. 4).  
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A systemic cellular immune response against HPV16 VLP and E7 
protein was observed in all HPV16+ patients after GM-CSF 
applications (Fig. 5 a-b). In 2 patients (G4 and G5), the number of 
IFNγ+ cells dropped at week 23-42 after the treatment (Fig. 5a-b), 
suggesting that a larger GM-CSF therapeutic window could be 
beneficial in sustaining the immune response, but we could not exclude 
a regulatory role of T cells in this inhibition since the number of Treg 
Foxp3+ cells slightly increased in some patients (Fig. 4). In some 
HPV16 negative patients, we also observed an immune response 
against HPV16 VLP, but not against HPV16 E7 (data not shown). 
Cross-reactivity has already been reported in PBMC from HPV-16 VLP 
vaccine recipients who can respond to L1-VLP from heterologous HPV 
types, suggesting the presence of conserved T cell epitopes 41. In 
contrast with VLP vaccines, which induce type-restricted immunity, the 
immune effect of GM-CSF is likely to be present for all the HPV 
genotypes. However, we were not able to confirm this statement 
because VLP and E7 proteins were not available for all the HPV types 
present in our cohort of patients.  
Concerning the clinical response, we analyzed patients with LSIL 
because the treatment of the lesion can be postponed without danger 
for the patient. Due to spontaneous and rapid regression rate in these 
patients 25, we were unable to show an effect of the treatment in this 
small cohort of patients.  
In conclusion, our study demonstrated the safety of our therapeutic 
approach and suggested that GM-CSF induces DC/LC, CTL and NK 
cell recruitment in the lesion and the induction of a systemic immune 
16 
response (humoral and cellular) against HPV. These results justify 
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Fig. 1: Schedule of enrollment. 
Fig. 2: Proliferation of normal keratinocytes (KN) and keratinocyte cell 
lines (means ±SD, n=3) in presence of GM-CSF (a).  Proliferation index 
(Ki67 staining) in biopsies of patients treated with GM-CSF or placebo 
gel (means ±SE, n=10 for GM-CSF and n=5 for placebo) (b).  
Fig. 3: Infiltration of DC/LC (CD1a+), CTL (CD8+) and NK cells 
(NKp46+) in cervical LSIL. Ratio of CD1a+ cells in the epithelium (a), of 
CD8+ cells in the epithelium (b) or in the stroma (c), of NKp46+ NK 
cells in the stroma (d) at visit D (week 2) and visit F (week 23-42) after 
application of GM-CSF or placebo gel. Empty symbols= patient G2.  
Fig. 4. Foxp3+ Treg cells in cervical biopsies. Number of Foxp3+ cells in 
the epithelium before (visit A/B) or after (visit D, week 2 or visit F, week 
23-42) applications of GM-CSF or placebo gel (a). Ratios of Foxp3+ 
cells in the stroma at visit D and F (b). Empty symbols= patient G2. 
Fig. 5: IFNγ production in response to HPV16 E7 or HPV16 L1-VLP in 
HPV16 positive patients. PBMC were stimulated overnight with HPV16 
E7 (a) or L1-VLP (b). (a) The percentage of IFNγ+ cells was determined 
in CD4+, CD8+ or CD56+CD16+CD3- (NK cells) gated cell populations. 
Antibody titers against HPV 16 (c) and HPV 31 (d) VLP in patient 
plasma samples. The antibody titer was determined in ELISA assay by 
serial dilutions of plasma samples. The assay was performed at least in 
duplicate. BT= before treatment.  
 
